ArticleJCO oncology advances2025

Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma.

Chia-Ching J Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.